Samsung Biologics Co. Ltd.
Samsung Biologics Co. Ltd.
04/14/2025 | Press release | Distributed by Public on 04/14/2025 20:42
Strategic biomanufacturing partner for multispecific antibodies
Resource Library
Whitepapers
Strategic biomanufacturing partner for multispecific antibodies
Multispecific antibodies, including bispecifics, represent a promising class of next-generation biologics as they offer enhanced efficacy and safety. However, their development and manufacturing present significant technical and regulatory complexities.
Our latest whitepaper outlines key considerations for addressing these challenges - from molecular design and process development to scalable manufacturing strategies.
Learn how Samsung Biologics applies seven strategic pillars to support the efficient development of multispecific antibodies.
Multispecific antibodies, including bispecifics, represent a promising class of next-generation biologics as they offer enhanced efficacy and safety. However, their development and manufacturing present significant technical and regulatory complexities.
Our latest whitepaper outlines key considerations for addressing these challenges - from molecular design and process development to scalable manufacturing strategies.
Learn how Samsung Biologics applies seven strategic pillars to support the efficient development of multispecific antibodies.
Attached
- Strategic biomanufacturing partner for multispecific antibodies
Samsung Biologics Co. Ltd. published this content on April 14, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 15, 2025 at 02:43 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]